AEON Biopharma, Inc. Class A (AEON)

Over the past six months, AEON Biopharma's stock price has been impacted by several events. In November 2025, positive initial comparative analytical results for ABP-450 were reported, and two financing transactions were announced to strengthen the balance sheet and accelerate the ABP-450 program. In December 2025, the execution of an Exchange Agreement with Daewoong was announced. An FDA Biosimilar Biological Product Development Type 2a meeting in January 2026 provided constructive feedback, but the market reacted negatively. In February 2026, AEON filed for an offering of shares by selling stockholders. In March 2026, John Bencich was appointed as Chief Financial Officer, and the full-year 2025 financial results were reported, showing a net loss of $39.2 million. The company's stock price has seen a positive trend over the past six months, and analysts increased the price target to US$6.70 in March 2026.

There is no explicit information indicating significant demand seasonality for AEON Biopharma's products or services. Seasonality is not a highlighted factor in the available information.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection, a proprietary botulinum toxin complex, for various medical conditions, particularly in the neuroscience market. Their lead product candidate, ABP-450, is being developed as a biosimilar to BOTOX for therapeutic indications and is currently undergoing Phase 2 studies for cervical dystonia, chronic and episodic migraine, gastroparesis and post-traumatic stress disorder. ABP-450 is the same botulinum toxin complex marketed by Evolus, Inc. as Jeuveau for cosmetic indications.

AEON Biopharma, Inc. is headquartered in Irvine, California, United States. They possess exclusive development and distribution rights for therapeutic indications of ABP-450 in key markets, including the United States, Canada, the European Union, the United Kingdom, and certain other international territories. ABP-450 has already been approved as a biosimilar in India, Mexico, and the Philippines. Daewoong Pharmaceutical manufactures ABP-450 in a facility approved by the FDA, Health Canada, and the European Medicines Agency.

AEON Biopharma's reputation has been influenced by positive feedback from the FDA regarding its analytical similarity strategy for ABP-450 and positive initial comparative analytical results for ABP-450. The appointment of John Bencich as Chief Financial Officer and the acceptance of an abstract for presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting further highlight ongoing corporate and scientific activities. Analyst sentiment is generally positive. However, the failure of a Phase 2 migraine trial in June 2024 and the market's negative reaction to positive FDA feedback in January 2026 have impacted reputation.

The ownership structure of AEON Biopharma is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 8.65% to 9.50% of the stock, insiders own about 39.96%, and public companies and retail investors account for approximately 50.54%. Major institutional owners include Dauntless Investment Group, LLC, Vanguard Group Inc, and Geode Capital Management, Llc. Daewoong Co., Ltd. is a significant public company shareholder, holding approximately 47.46% of the shares. Robert E. Bancroft is a major individual owner.